A PHASE 1/2 OPEN-LABEL PLATFORM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MULTIPLE AMIVANTAMAB-BASED THERAPEUTIC COMBINATIONS IN PARTICIPANTS WITH ADVANCED, UNRESECTABLE LUNG CANCER (LC)

Registry ID

PLATFORMPANSC2001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

JANSSEN INC

Start date

2024-04-22

Last update

2022-09-09

Conditions

• ADVANCED LUNG CANCER

Related clinical trials

• A RANDOMIZED PHASE 3 STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) AND PEMBROLIZUMAB, WITH OR WITHOUT PLATINUM CHEMOTHERAPY, IN SUBJECTS WITH NO PRIOR THERAPY FOR ADVANCED OR METASTATIC PD-L1 TPS <50% NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG07)
• PREVALENCE AND CLINICAL RELEVANCE OF VENTILATION HETEROGENEITY AND LUMINAL CELLULAR INFLAMMATION IN LUNG CANCER PATIENTS PRIOR TO LUNG RESECTION

View on source registry